C.R. Bard Inc. (NYSE:BCR) shares hit a new 52-week high on Tuesday . The stock traded as high as $238.23 and last traded at $237.69, with a volume of 204,921 shares. The stock had previously closed at $234.75.

BCR has been the topic of several research reports. Zacks Investment Research lowered C.R. Bard from a “buy” rating to a “hold” rating in a research report on Tuesday, April 12th. Leerink Swann increased their target price on C.R. Bard from $196.00 to $205.00 and gave the stock a “market perform” rating in a research report on Wednesday, March 30th. Barclays PLC increased their target price on C.R. Bard from $212.00 to $224.00 and gave the stock an “equal weight” rating in a research report on Tuesday, May 24th. Needham & Company LLC reaffirmed a “hold” rating on shares of C.R. Bard in a research report on Tuesday, May 24th. Finally, Bank of America Corp. reaffirmed a “buy” rating on shares of C.R. Bard in a research report on Monday, May 23rd. Nine analysts have rated the stock with a hold rating and six have issued a buy rating to the company. C.R. Bard has a consensus rating of “Hold” and a consensus target price of $220.13.

The stock has a 50 day moving average price of $225.13 and a 200 day moving average price of $203.20. The firm has a market cap of $17.36 billion and a price-to-earnings ratio of 160.14.

C.R. Bard (NYSE:BCR) last announced its quarterly earnings data on Wednesday, April 27th. The company reported $2.34 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.17 by $0.17. The business earned $873.50 million during the quarter, compared to analyst estimates of $845.77 million. During the same quarter in the prior year, the company earned $2.10 earnings per share. The company’s quarterly revenue was up 6.6% on a year-over-year basis. On average, equities research analysts predict that C.R. Bard Inc. will post $10.15 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 29th. Investors of record on Monday, July 18th will be issued a $0.26 dividend. This is a boost from C.R. Bard’s previous quarterly dividend of $0.24. The ex-dividend date is Thursday, July 14th. This represents a $1.04 annualized dividend and a yield of 0.44%.

In related news, CFO Christopher S. Holland sold 3,970 shares of the stock in a transaction that occurred on Friday, May 27th. The shares were sold at an average price of $219.89, for a total value of $872,963.30. Following the transaction, the chief financial officer now directly owns 31,306 shares in the company, valued at $6,883,876.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Tony L. White sold 1,200 shares of the stock in a transaction that occurred on Thursday, May 5th. The shares were sold at an average price of $216.19, for a total transaction of $259,428.00. Following the completion of the transaction, the director now owns 14,671 shares in the company, valued at $3,171,723.49. The disclosure for this sale can be found here.

A number of institutional investors have made changes to their positions in the stock. Daiwa Securities Group Inc. raised its position in shares of C.R. Bard by 33.3% in the fourth quarter. Daiwa Securities Group Inc. now owns 6,000 shares of the company’s stock valued at $1,137,000 after buying an additional 1,500 shares in the last quarter. Herndon Capital Management LLC purchased a new stake in C.R. Bard during the fourth quarter valued at $1,428,000. SECOR Capital Advisors LP raised its stake in C.R. Bard by 118.3% in the fourth quarter. SECOR Capital Advisors LP now owns 7,720 shares of the company’s stock valued at $1,462,000 after buying an additional 4,184 shares during the period. Deere & Co. raised its stake in C.R. Bard by 1.3% in the fourth quarter. Deere & Co. now owns 9,227 shares of the company’s stock valued at $1,748,000 after buying an additional 118 shares during the period. Finally, Trexquant Investment LP purchased a new stake in C.R. Bard during the fourth quarter valued at $1,862,000.

C. R. Bard, Inc (Bard) and its subsidiaries are engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.